An Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's Disease

NCT02939391 Phase 2 COMPLETED

The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score between KW-6356 and placebo in subjects with early Parkinson's disease in Japan.

Details

Lead sponsor	Kyowa Kirin Co., Ltd.
Phase	Phase 2
Status	COMPLETED
Enrolment	175
Start date	2016-09
Completion	2017-12-08

Conditions

• Parkinson's Disease

Interventions

• KW-6356
• KW-6356
• Placebo

Primary outcomes

• Change from baseline in the Movement disorder society-unified Parkinson's disease rating scale(MDS-UPDRS) partⅢ score — Up to 12 weeks after dosing

Countries

Japan